Abstract:In our hemophilia and von Willebrand patients we have since 1977 regularly analyzed HBs Ag, anti-HBs and anti-HBc. In our experience almost all of the patients with hemophilia A or von Willebrand's disease who have received continuous prophylactic treatment or frequent on demand treatment with factor VIII concentrates (Hemofil@, Octonative@ and AHF@, fraction I-0 respectively) for 2-3 years have developed antibodies to the surface and/or the core antigens of the hepatitis B virus (HBV). We have regarded this as a result of repeated minor infections with HBV transmitted by the factor VIII concentrates. In accordance with this view patients who have developed antibodies have maintained their antibody titers. In 1981 we investigated 19 patients all of whom had HBV antibodies, but none was Hbantigen positive. However, at reexamination 1984 five of these patients were found to have inprotective levels of antibodies. In addition, one of the patients had earlier a low anti-HAV IgG titre which also had disappeared during a two years period. Three of these patients had von Willebrand's disease and were treated with fraction I{ throughout the observation period. The other two patients with hemophilia A had during this three years period changed from treatment with Hemotil to treatment with Octonative. It is well known that even highly purified concentrates contain 200-500 mg IgG per 100 ml. This would of course imply the possibility of passive immunization of the recipients. Taking the long half life of the immunoglobulins and the frequent treatments into consideration even a low frequency of batches containing anti-HBs or anti-HBc would probably in these patients lead to long-standing levels of anti-HBc and/or anti-HBs. During the last 2-3 years the AIDS problem and the possible transfer of an AIDS transmitting agent present in the blood products have prompted a much more vigorous screening of the blood donors. Before the identification of HTLV III as a very likely cause of AIDS, hepatitis B markers were best correlated to AIDS. After a more careful selection of blood donors in order to exclude possible AIDS carriers it is reasonable to assume that also the frequency of anti-HBs/anti-HBc positive donors has decreased. It seems essential to us that hemophiliacs previously regarded as immune to HBV are retested and vaccinated if they have low or no levels of anti-HBs. The possibility of passive immunization through treatment should also be considered in the discussion and evaluation of HBV infectivity of different factor concentrates. These patients have later been vaccinated against hepatitis B and all of them have responded normally and developed antibodies. Four of these patients had no HTLV III antibodies and Th.rfiupp rstios of >1.1 (reference value >0.8). One hemophilia A patient had HTLV III antibodies and a low Th"rfiupp rotio, 0.5, but even he developed HB, antibodies normally after vaccination.

Modeling Power Portfolio with Supply Contracts for Mitigating Risks of Serving Uncertain Demand

Sirt1 inhibits kidney stones formation by attenuating calcium oxalate-induced cell injury

Overexpression of sirtuin 1 attenuates calcium oxalate-induced kidney injury by promoting macrophage polarization

Do Factor VIII Concentrates Cause Passive Immunization to Hepatitis B in Multitransfused Patients?

PPARγ agonist alleviates calcium oxalate nephrolithiasis by regulating mitochondrial dynamics in renal tubular epithelial cell

[Effect of Rongshi Granule on Renal Stone Formation and Osteopontin Expression in Rat Urolithiasis Model].

Effects of RongShi granule on renal stone formation in rat urolithiasis model

Inhibition of AT1R/IP3/IP3R-mediated Ca 2+ release protects against calcium oxalate crystals-induced renal oxidative stress

Inhibitory role of microRNA-484 in kidney stone formation by repressing calcium oxalate crystallization via a VDR/FoxO1 regulator axis

Selenium participates in the formation of kidney stones by alleviating endoplasmic reticulum stress and apoptosis of renal tubular epithelial cells

Oxalate-induced changes in renal epithelial cell function: role in stone disease

Oxalate-induced apoptosis through ERS-ROS–NF-κB signalling pathway in renal tubular epithelial cell

Sirtuin1 inhibits calcium oxalate crystal-induced kidney injury by regulating TLR4 signaling and macrophage-mediated inflammatory activation

Identification of Resolvin D1 and Protectin D1 as Potential Therapeutic Agents for Treating Kidney Stones

Sirtuin1 Suppresses Calcium Oxalate Nephropathy via Inhibition of Renal Proximal Tubular Cell Ferroptosis Through PGC‐1α‐mediated Transcriptional Coactivation

Is there equity in emergency medical care? Waiting times and walk-outs in South Western Sydney hospital emergency departments.

The Altered Proteomic Landscape in Renal Tubular Epithelial Cells under High Oxalate Stimulation

Occurrence and etiologic significance of Cryptococcus neoformans in a cutaneous lesion of a cat.

Oxalate as a potent promoter of kidney stone formation

Melatonin exerts a protective effect in ameliorating nephrolithiasis via targeting AMPK/PINK1-Parkin mediated mitophagy and inhibiting ferroptosis in vivo and in vitro

Oxalate regulates crystal-cell adhesion and macrophage metabolism via JPT2/PI3K/AKT signaling to promote the progression of kidney stones